RCS - Oncimmune Hldngs PLC - ‘Winning in Business in Spain’ Award

Oncimmune HoldingsAnnouncement

21/02/2020 07:00

For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20200221:nRSU6773Da

RNS Number : 6773D  Oncimmune Holdings PLC  21 February 2020

Oncimmune Holdings plc

("Oncimmune" or the "Company")

 

Oncimmune receives 'Winning in Business in Spain' award for distribution of
EarlyCDT(®) Lung in Spain

 

21 February 2020 - Oncimmune Holdings plc (AIM: ONC.L), a leading global
immunodiagnostics group, is pleased to announce it has been awarded the
'Winning in Business in Spain' award at the Department for International
Trade's (DIT) UK-Spain Business Awards held on 20th February 2020 at the
Madrid Stock Exchange in Spain.

 

These awards celebrate the extensive commercial relationships between the
United Kingdom and Spain.

 

The DIT's introduction of Sabartech has enabled Oncimmune to build its
successful distribution partnership with Sabartech, which has led to making
EarlyCDT Lung available in Spain and Portugal.

 

Javier Sarasqueta, Co-founder and CEO of Sabartech said "Sabartech and
Oncimmune have developed a great partnership that has helped launch EarlyCDT
Lung in the Spanish market. We are looking forward to building on this to
improve the early detection of lung cancer in both the private and public
healthcare systems. This award is a fantastic recognition of all we have
achieved so far."

 

Dr Adam M Hill, CEO of Oncimmune said: "This award is testament to the strong
relationship we have fostered with Sabartech. Every year there are 23,000 lung
cancer deaths in Spain(1). The key to improving lung cancer survival is early
detection and we are delighted that our EarlyCDT Lung test is continuing to
gain momentum in screening in Spain and beating cancer, one test at a time."

 

( 1 ) GLOBOCAN 2018 (WHO)

 

 

-Ends-

 

 

For further information:

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.com

 

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, Victoria Ayton

+44 (0)20 3829 5000

 

finnCap (Joint Broker)

Geoff Nash, Matthew Radley, Tim Redfern

+44 (0)20 7220 0500

 

Bryan, Garnier & Co Limited (Joint Broker)

Phil Walker, Dominic Wilson

+44 (0)20 7332 2500

 

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

oncimmune@fticonsulting.com

+44 (0)20 3727 1000

 

 

About Oncimmune

Beating cancer, one test at a time

 

The battle against cancer hinges on early detection and then the delivery of
effective treatment. Oncimmune is working to revolutionise both the detection
of cancer and its treatment by harnessing the sophisticated disease detecting
capabilities of the immune system to find cancer in its early stages. Our
range of diagnostic tests assist clinicians to identify the presence of cancer
four years or more before standard clinical diagnosis, whilst our technology
platform and sample biobanks are helping healthcare companies to develop new
cancer treatments.

 

Oncimmune was founded in 2002 and launched its platform technology in 2009,
followed by its first commercial tests, EarlyCDT Lung and EarlyCDT Liver. To
date, over 160,000 tests have been performed for patients worldwide. EarlyCDT
Lung was also used in what is believed to be the largest randomised controlled
trial for the early detection of lung cancer using biomarkers, the successful
National Health Service (NHS) ECLS trial of 12,209 high-risk smokers in
Scotland which demonstrated EarlyCDT Lung reduced the incidence of patients
with late-stage lung cancer or unclassified presentation at diagnosis,
compared to standard clinical practice.

 

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a
discovery research centre in Dortmund, Germany and in London, UK and a partner
representative office in Shanghai, China. Oncimmune joined the Alternative
Investment Market (AIM) of the London Stock Exchange in May 2016 under the
ticker ONC.L.

 

What is EarlyCDT Lung?

 

A blood test using a panel of seven immunogenic proteins for the testing of
tumour-related antibodies specific to lung cancer.

 

For more information, visit www.oncimmune.com (http://www.oncimmune.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.   END  NRADBGDDRDDDGGG